Ionis Pharmaceuticals: Buy Rating Backed by Olezarsen's Potential in sHTG Market

Ionis Pharmaceuticals has been given a Buy rating by Bank of America Securities analyst Jason Gerberry due to promising prospects in their clinical trials for olezarsen, targeting severe hypertriglyceridemia. The Phase 3 CORE study is expected to show significant benefits in reducing acute pancreatitis events, which is crucial for commercial viability in the sHTG market. With a price objective of $63.00 USD, Ionis Pharmaceuticals is seen as an attractive investment opportunity.

Ionis Pharmaceuticals, a biotechnology company specializing in RNA-targeted therapies, has received a Buy rating from Bank of America Securities analyst Jason Gerberry, who has set a $63.00 price target for the stock. The analyst's optimism is driven by the company's ongoing clinical trials for olezarsen, a potential treatment for severe hypertriglyceridemia (sHTG).

The Phase 3 CORE study, currently underway, aims to demonstrate significant benefits in reducing acute pancreatitis (AP) events, a critical complication associated with sHTG. If successful, this could significantly enhance the commercial viability of olezarsen in the broader sHTG market, which is often a silent but potentially dangerous condition.

Gerberry's positive outlook is supported by statistical analyses indicating a favorable likelihood of achieving statistically significant results in reducing AP events, even with a modest reduction rate. The enriched cohort within the study, which is expected to drive most AP events, further bolsters the probability of demonstrating these benefits. The analyst's price target of $63.00 USD reflects his belief that Ionis Pharmaceuticals is well-positioned to capitalize on its advancements, making it an attractive investment opportunity.

Additionally, on August 6, H.C. Wainwright reiterated a Buy rating on the stock with a $65.00 price target, further validating the positive sentiment surrounding Ionis Pharmaceuticals [1].

In a separate development, Tweedy Browne Co. All Funds (US) trimmed its stake in Ionis Pharmaceuticals in Q2 2025, despite the stock's strong performance. The firm's move reflects a strategic rebalancing towards undervalued, long-term opportunities. Despite the trimming, Ionis Pharmaceuticals' valuation remains attractive, with a fair value estimate of $58.19 per share—40% above its current price [2].

References:
[1] https://www.tipranks.com/news/ratings/promising-prospects-for-ionis-pharmaceuticals-buy-rating-backed-by-olezarsens-potential-in-shtg-market-ratings
[2] https://www.ainvest.com/news/tweedy-browne-q2-2025-portfolio-shifts-case-rebalancing-global-opportunities-2508/